DBS constructive on China's innovative drug sector, sees Q4 buying chances
DBS Hong Kong stays constructive on China's innovative drug sector, buoyed by rising central government support, with buying opportunities flagged for the fourth quarter this year. China is targeting 20 percent compound annual growth in the sector from 2026 to 2030, up from…